Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRITE data on BV beyond progression (BBP)

被引：1
|
作者：
Cohn, A. L.
Bekaii-Saab, T.
Bendell, J. C.
Hurwitz, H.
Kozloff, M.
Roach, N.
Tezcan, H.
Feng, S.
Sing, A.
Grothey, A.
机构：
[1] Rocky Mt Canc Ctr, Denver, CO USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Ingalls Hosp, Harvey, IL USA
[6] Univ Chicago, Harvey, IL USA
[7] C3, Alexandria, VA USA
[8] North Idaho Canc Ctr, Coeur Dalene, ID USA
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Mayo Clin, Coll Med, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3596
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cumulative Exposure to Bevacizumab (BV) After Progression Correlates With Increased Survival in Patients (pts) With Metastatic Colorectal Cancer (mCRC): a Time-dependent Analysis of the ARIES Observational Cohort Study
    Grothey, A.
    Bekaii-Saab, T. S.
    Hurwitz, H.
    Kozloff, M.
    Roach, N.
    Mun, Y.
    Fish, S.
    Flick, E. D.
    Dalai, D.
    Cohn, A. L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S395 - S395
  • [22] CLINICAL OUTCOMES (COS) BY SEX IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): PRELIMINARY RESULTS FROM ARIES, A BEVACIZUMAB (BV) OBSERVATIONAL COHORT STUDY (OCS)
    Fischbach, N. A.
    Wozniak, A.
    Kumar, P.
    Kosty, M.
    Beatty, S.
    Teng, S. L.
    Flick, E. D.
    Sing, A. P.
    Lynch, T. J., Jr.
    ANNALS OF ONCOLOGY, 2010, 21 : 142 - 142
  • [23] Observational cohort study focused on treatment continuity of patients (pts) treated with XELOX plus bevacizumab (BV) for previously untreated metastatic colorectal cancer (mCRC).
    Kotaka, Masahito
    Ikeda, Husao
    Ikumoto, Taro
    Tsuzie, Masaki
    Yoshioka, Shinichi
    Nakamoto, Yoshihiko
    Ishii, Takaaki
    Goto, Saori
    Itami, Atsushi
    Kato, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [24] Serious wound healing complications (SWHC) following surgery in patients with metastatic colorectal cancer (RNCRC) receiving bevacizumab (BV): Results from the brite observational cohort study (OCS)
    Sugrue, M.
    Purdie, D.
    Feng, S.
    Flynn, P.
    Grothey, A.
    Sargent, D.
    Berlin, J.
    Kabbinavar, F.
    Dong, W.
    Kozoff, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 82 - 83
  • [25] Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizurnab (BV): results from the BRITE registry
    Sing, A.
    Sugrue, M.
    Chiruvolu, R.
    Yi, J.
    Purdie, D.
    Dong, W.
    Grothey, A.
    Kozloff, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 249 - 249
  • [26] Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS)
    Wozniak, A. J.
    Garst, J.
    Jahanzeb, M.
    Kosty, M. P.
    Vidaver, R.
    Beatty, S.
    Teng, S.
    Flick, E. D.
    Sing, A.
    Lynch, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] SAFETY OUTCOMES ASSOCIATED WITH LONG-TERM, CONTINUOUS EXPOSURE TO BEVACIZUMAB (BV) AND CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH MCRC: RESULTS FROM THE BRITE OBSERVATIONAL COHORT STUDY
    Kozloff, M.
    Berlin, J.
    Flynn, J.
    Grothey, A.
    Kabbinavar, F.
    Sargent, D.
    Dong, W.
    Purdie, D.
    Sugrue, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 132 - 132
  • [28] CLINICAL OUTCOMES (CO) FOR SPECIAL POPULATIONS OF PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): RESULTS FROM ARIES, A BEVACIZUMAB (BV) OBSERVATIONAL COHORT STUDY (OCS)
    Wozniak, A. J.
    Garst, J.
    Jahanzeb, M.
    Kosty, M.
    Vidaver, R.
    Beatty, S.
    Teng, S. L.
    Flick, E. D.
    Sing, A. P.
    Lynch, T. J.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S100 - S101
  • [29] Development of cavitation while on bevacizumab (BV) therapy in patients (pts) with non-small cell lung cancer (NSCLC): Results from ARIES-A bevacizumab (BV) treatment observational cohort study (OCS)
    Kosty, M. P.
    Kumar, P.
    Wozniak, A.
    Jahanzeb, M.
    Chung, C.
    Wang, L.
    Sing, A.
    Lynch, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS)
    Fischbach, N. A.
    Spigel, D.
    Brahmer, J.
    Garst, J.
    Robles, R.
    Chung, C.
    Wang, L.
    Sing, A.
    Lynch, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345